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1. Introduction
Associated with high morbidity and mortality, severe group B streptococcal (GBS)
infections should be treated promptly with antimicrobial agents characterized by both a good
diffusion at the site of infection and a short bactericidal lag time. GBS are uniformly
susceptible to penicillin or ampicillin at concentrations usually achieved in blood or
cerebrospinal fluid. Gentamicin alone is not regarded as clinically useful in the treatment of
GBS infections; however, to accelerate GBS killing, penicillin or another h-lactam given in
combinationwith gentamicin is recommended to start the therapy [1,2].Minimum inhibitory
concentrations (MIC) of gentamicin (G) for GBS isolated in Belgium range from 16 to 256
mg/L [3]. These observed MICs of gentamicin are often higher than G-MICs for
Enterococcus faecalis with low-level resistance, but lower than the G-MICs of E. faecalis
with a high-level of resistance to G. This study was undertaken to determine conditions
required for eradication of GBS in vitro, especially for strains with the highest MICs
determined for gentamicin. The potential synergism and killing kinetics of penicillin and
gentamicin individually or in combination (ratio 1:1), at different concentrations, were
investigated against strains of GBS.0531-5131/ D
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2.1. Bacterial isolates
Six strains of GBS isolated from clinically important sources from neonates or adults
with invasive infections, submitted to the Belgian reference laboratory for GBS in 2002–
2003 and preserved at 70 8C, were selected either for their known low MIC or higher
MIC to gentamicin (16 to 128 mg/L). As positive and negative controls, for comparison in
the synergy and timed antibiotic-killing studies, two strains of E. faecalis either with low
or high level of resistance to gentamicin were used.
2.2. Determination of MICs and kinetic studies: determination of killing curves
Determinations of MICs of penicillin and gentamicin were performed for GBS and E.
faecalis isolates using Etest strips according to the Etest ABBiodisk method (Sweden),
respectively on Muller Hinton agar supplemented or not with 5% of sheep blood.
Timed killing assays with penicillin were performed according to an Etest ABBiodisk
original procedure. Each isolate was tested twice. A killing curve master plate was prepared
by flooding a 14-cm plate of Muller Hinton agar (with or without sheep blood agar) with a
1:10 dilution of a 0.5 McFarland inoculum suspension. The excess fluid was pipetted and
drained and the plate was dried for 15 min in an incubator. Then six Etest strips of penicillin
were applied upon the surface using a template. A growth control area (33 mm2) was
sampled with a 1-Al loop and then streaked in the bcontrolQ quadrant of CFU (colony forming
units) of a sheep blood agar plate, the bt =0 plateQ. Along an Etest strip at the levels of the
known MIC4, MIC8 and MIC16, areas were sampled and streaked in the respective
CFU quadrants of the same t =0 plate. The master plate was then re-incubated and the CFU
t=0 plate was incubated at 35 8C. After 2 h, the master plate was taken out of the incubator
and sampled as previously along another Etest strip: the control and MIC multiples. The
samples were streaked in the quadrants of another blood agar plate, the t =2 plate. Again the
master plate was re-incubated and the t=2 CFU plate incubated. The procedure was repeated
at incubation intervals 4 h, 8 h, and 20 h. After overnight incubation, the colonies or the
surviving organisms per quadrant were enumerated on the initial t =0 plate and repeatedly on
the plates prepared after 2, 4, 8 and 20 h. The amounts of CFU/9 mm2 were plotted versus
sampling time for the control and MIC multiples.
2.3. Synergy experiments
Determination of MICs in a combination test was performed according to an Etest
ABBiodisk original procedure as follows. The Muller Hinton agar (supplemented or not
with 5% sheep blood) plate was inoculated as for the determination of MICs of individual
drugs, then a strip of gentamicin (range of 0.016–256 mg/L) was placed on the agar
surface, its position was marked and the plate was left for 1 h on the bench. After 1 h, the
strip was removed and a penicillin strip was positioned onto the imprint of the first
antibiotic to have a ratio of 1:1, the gradients were then superimposed. Immediately the
plate was transferred at 35 8C and incubated overnight. MICs of each antibiotic in the
combination test was read and compared to the MICs of each antibiotic individually
determined. A synergistic effect was considered to be present when MIC of drugs in the
combination was N2 dilutions lower than the MIC of the most active single drug.
Fig. 1. Growth of E. faecalis without antibiotic (control) and median killing curves for gentamicin low level (A)
or high level (B) resistance E. faecalis for penicillin (P) alone or in combination with gentamicin (P+G) at
different concentrations (4-fold and 16-fold penicillin MIC).
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compared to single drugs.
Kinetic studies were performed according to a combination of the two ABBiodisk
procedures described above. The kinetic testing procedure was performed after a previous
step, in which gentamicin strips were left for 1 h upon the plate, further removed and
replaced with penicillin strips. Timed killing curves determined for the combination at
different concentrations were respectively compared to killing times observed with
penicillin alone. The combination of antibiotics was considered synergistic to reduce the
killing time when it eradicated GBS in a shorter time than penicillin alone.
3. Results
The range of MICs of penicillin for the 6 isolates of GBS was 0.032–0.047 mg/L. For
the E. faecalis, the MICs were respectively 1.5 and 6 mg/L for the isolates with a low level
or a high level resistance to gentamicin.
Either for all GBS isolates or for the two E. faecalis strains, after overnight incubation,
penicillin and gentamicin in combination were not more effective than penicillin alone to
eradicate isolates in culture. MICs of penicillin in the combination were within +1 dilution
compared to penicillin alone.
In the kinetic experiments, for all strains, growth of bacteria occurred in the absence of
antibiotic (control) and rapidly exceeded 500 CFU per sample. As expected, Fig. 1A
shows the synergistic effect of penicillin plus gentamicin against the strain of E. faecalis
with a low level of resistance to gentamicin. To eradicate the strain in culture submitted toFig. 2. Growth of GBS without antibiotic (control) and median killing curves for two strains of GBS for penicillin
(P) alone or in combination with gentamicin (P+G) at different concentrations (4-fold and 16-fold penicillin
MIC).
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necessary. When penicillin was associated to gentamicin, killing was enhanced: the killing
times for concentrations of penicillin at 4-fold and 16-fold its MIC were, respectively, 4
and 2 h. Fig. 1B illustrates the lack of synergism of penicillin plus gentamicin against the
strain of E. faecalis highly resistant to gentamicin. The killing curves of penicillin alone or
in combination with gentamicin are rather parallel and close to each other. In all the tested
conditions, to eradicate the strain, overnight incubation was mandatory. On the contrary,
compared with penicillin alone, nearly no accelerated killing was observed for any GBS
isolate with the combination penicillin plus gentamicin even for a concentration of 16-fold
MIC of penicillin (indifference); moreover, for 3 isolates, a reduced killing was observed
in the combination tests (antagonism). Representative data are shown in the Fig. 2.
4. Discussion
For our kinetics studies and investigation for synergistic effect, performed according to
original ABBiodisk procedures, the expected results observed with the strains of E.
faecalis validated the procedures used in this study. But the observed results with GBS
strains were quite different of expectation: no clear synergy was demonstrated with the
combination penicillin plus gentamicin (1:1) used, independently of values of gentamicin–
MICs; moreover, the killing was reduced for half of the isolates of GBS by comparison
with penicillin alone. These in vitro studies, the conditions of which vary considerably
from the pharmacodynamic and pharmacologic conditions of clinical in vivo use of a
combination therapy, just show that any h-lactam in combination with gentamicin did not
demonstrate necessarily the expected accelerated killing of GBS. To determine which
combination and ratio of antimicrobial agents could be used to achieve this goal, and to
recommend wisely which regimen should be administered to treat patients with invasive
GBS infections, further evaluation should be performed on these strains with other ratio or
other h-lactams, in combination with gentamicin.
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